Immunovant Inc IMVT

Healthcare Biotechnology

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

NDAQ:IMVT - Post by User

Immunovant Inc

<< Previous

Bullboard Posts

Post by whytestockson Dec 04, 2024 12:00pm

13 Views

Post# 36345329

(IMVT) Investment Analysis and Advice

JUST IN: $IMVT (IMVT) Investment Analysis and Advice2024-12-04 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...IMVT - (IMVT) Investment Analysis and Advice

<< Previous

Bullboard Posts

Thunder Gold makes generational discovery